Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients | Zendy

Óscar Len | Zendy; Joan Gavaldà | Zendy; José María Aguado | Zendy; Núria Borrell | Zendy; Carlos Cervera | Zendy; José Miguel Cisneros | Zendy; Valentín CuervasMons | Zendy; Mercè Gurguí | Zendy; Pilar MartínDávila | Zendy; Miguel Montejo | Zendy; Patricia Muñóz | Zendy; Germán Bou | Zendy; Jordi Carratalà | Zendy; Julián TorreCisneros | Zendy; Albert Pahissa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients

Author(s) -

Óscar Len,

Joan Gavaldà,

José María Aguado,

Núria Borrell,

Carlos Cervera,

José Miguel Cisneros,

Valentín CuervasMons,

Mercè Gurguí,

Pilar MartínDávila,

Miguel Montejo,

Patricia Muñóz,

Germán Bou,

Jordi Carratalà,

Julián TorreCisneros,

Albert Pahissa

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/523590

Subject(s) - valganciclovir , ganciclovir , medicine , retinitis , cytomegalovirus , transplantation , regimen , betaherpesvirinae , surgery , gastroenterology , human cytomegalovirus , immunology , viral disease , herpesviridae , virus

Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant (SOT) recipients, either by direct injury or in association with chronic allograft rejection or other opportunistic infections. Ganciclovir is the treatment of choice, but this agent requires intravenous administration, which affects its feasibility for long-term use. Valganciclovir, which has an oral bioavailability of 60%, has proven to be useful for prophylaxis of CMV infection in high-risk SOT recipients and for treating retinitis in persons with acquired immunodeficiency syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research